Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma – second-line
Lisocabtagene maraleucel is in clinical development for the treatment of adult patients with high-risk, relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). In NHL, the affected lymphocytes start to multiply abnormally and begin to collect in certain parts of the body such as the lymph nodes. Aggressive or high-grade lymphomas tend to grow very quickly. Relapsed means the lymphoma has responded to treatment but then returns, and refractory means the lymphoma has not responded to the initial treatment. Treatment options for relapsed/refractory aggressive B-cell lymphoma are limited.
Lisocabtagene maraleucel is administered intravenously. It contains the patient’s white blood cells (T-cells) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). The CAR T-cells attach to a particular protein called CD19 on the surface of cancer cells resulting in the death of these cells. If licensed, lisocabtagene maraleucel will offer a treatment option for adult patients with high-risk, relapsed or refractory aggressive B-cell NHL.